NCT01152710View on ClinicalTrials.gov

Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2010

Conditions
Resectable Rectal Cancer Clinical Stage II and III
Interventions
DRUG

Capecitabine

Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends

Trial Locations (1)

1000

Institute of Oncology, Ljubljana

All Listed Sponsors
lead

Institute of Oncology Ljubljana

OTHER

NCT01152710 - Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer | Biotech Hunter | Biotech Hunter